Literature DB >> 17957461

Mannitol upregulates monocyte HLA-DR, monocyte and neutrophil CD11b, and inhibits neutrophil apoptosis.

Matthias Turina1, Aaron Mulhall, Sarah Gardner, Hiram C Polk, Frederick N Miller.   

Abstract

D-Mannitol is a substance widely used for both clinical applications as a strong diuretic and in basic research as a purportedly inert osmotic control substance. However, recent experiments have shown that mannitol is able to decrease neutrophil apoptosis in vitro by more than 25%. The aim of the current study was to assess mannitol's effects on two immune cell activation markers; CD11b on neutrophils and monocytes, and HLA-DR on monocytes. Exposure of diluted whole blood (1:10 in RPMI 1640) to increasing concentrations of mannitol for 24 h was associated with a significant increase in both monocyte and neutrophil CD11b expression in non-lipopolysaccharide (LPS)-stimulated samples. Monocyte HLA-DR, but not neutrophil HLA-DR, was significantly higher in the presence of 16.5 mM/l mannitol, whereas isoosmolar NaCl had no effect. Levels of IL-6 and TNF-alpha were not affected by mannitol in our model. All reagents were tested negative for endotoxin contamination. Together, these data indicate that mannitol may directly interact with neutrophils and monocytes. Further systematic evaluation is indicated to define the precise immunomodulating actions of mannitol, and to assess these effects in patients receiving such therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17957461     DOI: 10.1007/s10753-007-9051-1

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  50 in total

1.  The oxidation of mannitol.

Authors:  A N WICK; T N MORITA; L JOSEPH
Journal:  Proc Soc Exp Biol Med       Date:  1954-01

Review 2.  Monocyte deactivation--rationale for a new therapeutic strategy in sepsis.

Authors:  H D Volk; P Reinke; D Krausch; H Zuckermann; K Asadullah; J M Müller; W D Döcke; W J Kox
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

Review 3.  Hyperosmolar agents in neurosurgical practice: the evolving role of hypertonic saline.

Authors:  Alfred T Ogden; Stephan A Mayer; E Sander Connolly
Journal:  Neurosurgery       Date:  2005-08       Impact factor: 4.654

4.  Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites.

Authors:  M Hansson; A Asea; U Ersson; S Hermodsson; K Hellstrand
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

5.  Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients.

Authors:  M J Hershman; S H Appel; S R Wellhausen; G Sonnenfeld; H C Polk
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

6.  Modulation of macrophage proliferation by hyperglycemia.

Authors:  Y J Liu; A Saini; D J Cohen; B S Ooi
Journal:  Mol Cell Endocrinol       Date:  1995-10-30       Impact factor: 4.102

7.  Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils.

Authors:  S B Shappell; C Toman; D C Anderson; A A Taylor; M L Entman; C W Smith
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

8.  Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial.

Authors:  D J Dries; G J Jurkovich; R V Maier; T P Clemmer; S N Struve; J A Weigelt; G G Stanford; D L Herr; H R Champion; F R Lewis
Journal:  Arch Surg       Date:  1994-10

9.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.

Authors:  D De Groote; P F Zangerle; Y Gevaert; M F Fassotte; Y Beguin; F Noizat-Pirenne; J Pirenne; R Gathy; M Lopez; I Dehart
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

10.  Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial.

Authors:  Julio Cruz; Giulio Minoja; Kazuo Okuchi; Enrico Facco
Journal:  J Neurosurg       Date:  2004-03       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.